For the nine months ended September 30, 2010, the Company's marketing and selling expenses decreased 8%, or $15,000, to $185,000 compared to $200,000 for the comparable period in 2009. This decrease was primarily due to a decrease in personnel- related expenses, advertising and tradeshow expenses, offset by an increase in sales brokerage related expenses associated with the planned distribution of the nutritional products.
General and administrative expenses decreased 42%, or $1.4 million, to $1.9 million for the nine months ended September 30, 2010, compared to $3.3 million for the same period in 2009, primarily due to a reduction in personnel related costs through headcount reductions and reductions in executive compensation.
Research and development expenses decreased 61%, or $1.3 million, to $853,000 for the nine months ended September 30, 2010, compared to $2.2 million for the same period in 2009, primarily due to reductions in personnel and other expenses reflecting the deferral of development activities for certain product candidates.
The net loss for the nine months ended September 30, 2010, decreased 52%, or $2.7 million, to $2.4 million, compared with a net loss of $5.1 million for the same period in 2009. This decrease was primarily due to lower overall operating expenses.
About SCOLR Pharma:Based in Bothell, Washington, SCOLR Pharma, Inc. is a specialty pharmaceutical company focused on applying its formulation expertise and patented CDT platforms to develop novel prescription pharmaceutical, over-the-counter (OTC), and nutritional products. Our CDT drug delivery platforms are based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. For more information on SCOLR Pharma, please call 425-368-1050 or visit http:
|SOURCE SCOLR Pharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved